Meloxicam

Identification

Summary

Meloxicam is an NSAID used to treat osteoarthritis in adults, rheumatoid arthritis in adults, and juvenile rheumatoid arthritis in pediatrics.

Brand Names

Anjeso, Mobic, Qmiiz, Vivlodex

Generic Name

Meloxicam

DrugBank Accession Number

DB00814

Background

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis.¹ With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.^4,5

Type

Small Molecule

Groups

Approved, Vet approved

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Meloxicam (DB00814)

×

Close

Weight

Average: 351.401
Monoisotopic: 351.034747299

Chemical Formula

C₁₄H₁₃N₃O₄S₂

Synonyms

• Méloxicam
• Meloxicam
• Meloxicamum

External IDs

• N-1539
• N1539
• UH-AC 62XX
• UH-AC-62 XX
• UH-AC62

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication

Meloxicam is indicated for the symptomatic treatment of arthritis and osteoarthritis. In addition, it is indicated for the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above.¹⁰ Off-label uses include the treatment of dental or post-surgical pain. In addition to the above, meloxicam has also been studied in the treatment of neuropathic pain. ¹

Meloxicam, in combination with bupivacaine, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.¹³

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Treatment of	Dental pain		••• •••••
Symptomatic treatment of	Osteoarthritis		••••••••••••
Used in combination for symptomatic treatment of	Pain, inflammatory	Combination Product in combination with: Esomeprazole (DB00736)	••••••••••••		•••• •••• •• •••••••••• •••••• •••••• •••••••••• ••••••••••• ••••••••• •••••••	•••••••• ••••••• ••••••• ••••••
Used in combination for symptomatic treatment of	Pain, inflammatory	Combination Product in combination with: Esomeprazole (DB00736)	••••••••••••		•••• •••• •• •••••••••• •••••• •••••• •••••••••• ••••••••••• ••••••••• •••••••	•••••••• ••••••• ••••••• ••••••
Treatment of	Pain, neuropathic		••• •••••

Create Account

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Meloxicam is an anti-inflammatory, analgesic analgesic with antipyretic effects in fever.¹ Prostaglandins are substances that contribute to inflammation.⁷ This drug also exerts preferential actions against COX-2³, which may reduce the possible gastrointestinal effects of this drug.

In humans, meloxicam has demonstrated the ability to decrease erythrocyte sedimentation rate(ESR) in patients with rheumatoid arthritis, and to decrease ESR, C-reactive protein (CRP), as well as aquaporin-1 expression.¹ As with other NSAIDS, prolonged use of meloxicum can result in renal or cardiovascular impairment or thrombotic cardiovascular events.¹⁰

A note on gastrointestinal effects

As meloxicam preferentially inhibits COX-2, it is thought to cause less gastrointestinal irritation compared to other NSAIDS. Despite this, it still carries a risk of gastric inflammation, bleeding and ulceration.^5,10 In one study, patients on meloxicam suffered from gastrointestinal symptoms at a rate of 13% compared to 19% of those on diclofenac. GI events were found to be less severe in the meloxicam-treated patients.¹

Mechanism of action

Meloxicam inhibits prostaglandin synthetase (cylooxygenase 1 and 2) enzymes leading to a decreased synthesis of prostaglandins, which normally mediate painful inflammatory symptoms.⁷ As prostaglandins sensitize neuronal pain receptors, inhibition of their synthesis leads to analgesic and inflammatory effects. Meloxicam preferentially inhibits COX-2, but also exerts some activity against COX-1, causing gastrointestinal irritation.^1,10

Target	Actions	Organism
AProstaglandin G/H synthase 2	inhibitor	Humans
UProstaglandin G/H synthase 1	inhibitor	Humans

Absorption

The absolute bioavailability oral capsules after a dose was 89% in one pharmacokinetic study. Cmax was reached 5–6 hours after administration of a single dose given after the first meal of the day. The Cmax doubled when the drug was administered in the fasting state. Despite this, meloxicam can be taken without regard to food, unlike many other NSAIDS.^1,10

Meloxicam formulated for instillation with bupivacaine produced varied systemic measures following a single dose of varying strength. In patients undergoing bunionectomy, 1.8 mg of meloxicam produced a C_max of 26 ± 14 ng/mL, a median T_max of 18 h, and an AUC_∞ of 2079 ± 1631 ng*h/mL. For a 9 mg dose used in herniorrhaphy, the corresponding values were 225 ± 96 ng/mL, 54 h, and the AUC_∞ was not reported. Lastly, a 12 mg dose used in total knee arthroplasty produced values of 275 ± 134 ng/mL, 36 h, and 25,673 ± 17,666 ng*h/mL.¹³

Volume of distribution

The volume of distribution of meloxicam is 10-15L. Because of its high binding to albumin, it is likely to be distributed in highly perfused tissues, such as the liver and kidney.¹ Meloxicam concentrations in synovial fluid, measured after an oral dose, is estimated at 40% to 50% of the concentrations measured in the plasma.¹⁰ This drug is known to cross the placenta in humans.⁹

Protein binding

Meloxicam is about 99.4% protein bound, primarily to albumin.^1,3,10

Metabolism

Meloxicam is almost completely metabolized. CYP2C9 is the main enzyme responsible for the metabolism of meloxicam^1,6 with minor contributions from CYP3A4.¹⁰ Meloxicam has 4 major metabolites with no activity determined. About 60% of the ingested dose is metabolized to 5'-carboxy meloxicam from hepatic cytochrome enzyme oxidation of an intermediate metabolite, 5’-hydroxymethylmeloxicam.^6,8 Two other metabolites are likely produced via peroxidation.^6,10

Hover over products below to view reaction partners

• Meloxicam
  • 5'-hydroxymethyl meloxicam
    • 5'-carboxy meloxicam

Route of elimination

Meloxicam is mainly eliminated through metabolism. Its metabolites are cleared through renal and fecal elimination.³ Less than <0.25% of a dose is eliminated in the urine as unchanged drug.¹⁰ About 1.6% of the parent drug is excreted in the feces.¹

Half-life

The half-life of meloxicam is approximately 20 hours³, which is considerably longer than most other NSAIDS. It can therefore be dosed without the need for slow-release formulations.¹

Meloxicam applied together with bupivacaine for postsurgical analgesia had a median half-life of 33-42 hours, depending on dose and application site.¹³

Clearance

After an oral dose, the total clearance of meloxicam is 0.42–0.48 L/h.^1,3 The FDA label indicates a plasma clearance from 7 to 9 mL/min. No dose changes are required in mild to moderate renal or hepatic impairment. The use of meloxicam in patients with severe renal or hepatic impairment has not been studied. FDA prescribing information advises against it.¹⁰

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

The oral LD50 in rats is 98 mg/kg.¹¹ Signs and symptoms of overdose with meloxicam may include shallow breathing, seizure, decreased urine output, gastrointestinal irritation, nausea, vomiting, gastrointestinal bleeding, and black tarry stools.¹² In the case of an overdose, offer supportive treatment and attempt to remove gastrointestinal contents. Cholestyramine has been shown to enhance the elimination of meloxicam.¹¹

Pathways

Pathway	Category
Meloxicam Action Pathway	Drug action

Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">

Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Abacavir	Meloxicam may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abametapir	The serum concentration of Meloxicam can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Meloxicam can be increased when combined with Abatacept.
Abciximab	The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Abciximab.
Abemaciclib	The risk or severity of methemoglobinemia can be increased when Abemaciclib is combined with Meloxicam.

Food Interactions

• Avoid alcohol. The risk of gastrointestinal bleeding may be increased.
• Take with or without food. The absorption is unaffected by food.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Images

PreviousNext

International/Other Brands

Achefree (Achefree) / Acticam (Acromax Dominicana) / Aflamid (Anchor) / Afloxx (Lusa) / Aglan (Zentiva) / Ainecox (Cheminter) / Aldoron (Ivax) / Alentum (Lafrancol) / Algiflex (Biogen) / Aliviodol (Centrum) / Anaxicam (Caferma) / Anposel (Medipharm) / Antrend (Labormed) / Aponip (Pharmatec) / Areloger (Gerard) / Aremil (Magma) / Armex (Qintar Pharma) / Arrox (Xepa-Soul Pattinson) / Arsitec (Arsmedendi) / Artex (Pharmedic) / Arthrobic (Mekophar) / Arthrox (Pharmanel) / Articam (Standpharm) / Artipro (Helix) / Artriclox (Garmisch) / Artrifilm (G&R) / Artriflam (Sherfarma) / Artrilom (Pro.Med.CS) / Artrilox (Combiphar) / Artrox (PharmaBrand) / Aspicam (Biofarm) / Atiflam (Doctor Andreu) / Atrozan (Pharmstandard) / Auroxicam (Aurora) / Axius (Hersil)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Act Meloxicam	Tablet	15 mg	Oral	TEVA Canada Limited	2004-08-12	2021-07-30
Act Meloxicam	Tablet	7.5 mg	Oral	TEVA Canada Limited	2004-08-12	2021-07-30
Anjeso	Injection	30 mg/1mL	Intravenous	Baudax Bio, Inc.	2020-02-24	Not applicable
Meloxicam	Tablet	7.5 mg/1	Oral	Mylan Pharmaceuticals Inc.	2007-01-16	2007-01-16
Meloxicam	Tablet	7.5 mg/1	Oral	Caraco Pharmaceutical Laboratories, Ltd.	2008-11-12	Not applicable

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Apo-meloxicam	Tablet	15 mg	Oral	Apotex Corporation	2004-02-13	Not applicable
Apo-meloxicam	Tablet	7.5 mg	Oral	Apotex Corporation	2004-02-13	Not applicable
Auro-meloxicam	Tablet	15 mg	Oral	Auro Pharma Inc	2012-10-18	Not applicable
Auro-meloxicam	Tablet	7.5 mg	Oral	Auro Pharma Inc	2012-10-19	Not applicable
Ava-meloxicam	Tablet	15.0 mg	Oral	Avanstra Inc	2011-08-11	2014-08-21

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
NuDroxiPAK M-15	Meloxicam (15 mg/1) + Capsaicin (0.25 mg/1mL) + Menthol (60 mg/1mL) + Methyl salicylate (250 mg/1mL)	Kit	Oral; Topical	NuCare pharmceuticals,Inc.	2007-03-07	Not applicable
OCAM PROTECT 15 MG	Meloxicam (15 mg) + Esomeprazole magnesium trihydrate (20 mg)	Tablet, coated	Oral	LABORATORIOS LA SANTÉ S.A.	2011-04-20	Not applicable
OCAM PROTECT® 7.5 TABLETAS DE LIBERACIÓN RETARDADA	Meloxicam (7.5 mg) + Esomeprazole magnesium trihydrate (20 mg)	Tablet, coated	Oral	LABORATORIOS LA SANTÉ S.A.	2011-07-19	Not applicable
RUMONAL® PRO 15	Meloxicam (15 mg) + Esomeprazole magnesium trihydrate (20 mg)	Capsule, coated	Oral		2011-11-08	2018-05-03
RUMONAL® PRO 7.5	Meloxicam (7.5 mg) + Esomeprazole magnesium trihydrate (20 mg)	Capsule, coated	Oral		2011-10-28	2020-05-18

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Trepoxicam-7.5	Meloxicam (7.5 mg/1) + Histidine (50 mg/1)	Kit	Oral	Physician Therapeutics Llc	2011-01-31	Not applicable

Categories

ATC Codes

N01BB59 — Bupivacaine and meloxicam

• N01BB — Amides
• N01B — ANESTHETICS, LOCAL
• N01 — ANESTHETICS
• N — NERVOUS SYSTEM

M01AC56 — Meloxicam, combinations

• M01AC — Oxicams
• M01A — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
• M01 — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
• M — MUSCULO-SKELETAL SYSTEM

M01AC06 — Meloxicam

• M01AC — Oxicams
• M01A — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
• M01 — ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
• M — MUSCULO-SKELETAL SYSTEM

Drug Categories

• Agents causing hyperkalemia
• Agents that produce hypertension
• Amides
• Analgesics
• Analgesics, Non-Narcotic
• Anesthetics
• Anesthetics, Local
• Anti-Inflammatory Agents
• Anti-Inflammatory Agents, Non-Steroidal
• Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)
• Antiinflammatory and Antirheumatic Products
• Antiinflammatory and Antirheumatic Products, Non-Steroids
• Antirheumatic Agents
• COX-2 Inhibitors
• Cyclooxygenase Inhibitors
• Cytochrome P-450 CYP2C8 Substrates
• Cytochrome P-450 CYP2C9 Substrates
• Cytochrome P-450 CYP3A Substrates
• Cytochrome P-450 CYP3A4 Substrates
• Cytochrome P-450 Substrates
• Musculo-Skeletal System
• Nephrotoxic agents
• Nervous System
• Other Nonsteroidal Anti-inflammatory Agents
• Oxicams
• Peripheral Nervous System Agents
• Selective Cyclooxygenase 2 Inhibitors (NSAIDs)
• Sensory System Agents
• Sulfur Compounds
• Thiazines
• Thiazoles

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as benzothiazines. These are organic compounds containing a benzene fused to a thiazine ring (a six-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Benzothiazines

Sub Class

Not Available

Direct Parent

Benzothiazines

Alternative Parents

Alpha amino acids and derivatives / N-arylamides / 2,5-disubstituted thiazoles / Organosulfonamides / Benzenoids / 1,2-thiazines / Vinylogous acids / Heteroaromatic compounds / Secondary carboxylic acid amides / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds

show 4 more

Substituents

2,5-disubstituted 1,3-thiazole / Alpha-amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Benzothiazine / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Heteroaromatic compound / Hydrocarbon derivative / N-arylamide / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organic sulfonic acid or derivatives / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Organosulfonic acid amide / Organosulfonic acid or derivatives / Ortho-thiazine / Secondary carboxylic acid amide / Thiazole / Vinylogous acid

show 16 more

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

monocarboxylic acid amide, 1,3-thiazole, benzothiazine (CHEBI:6741)

Affected organisms

• Humans and other mammals

Chemical Identifiers

UNII

VG2QF83CGL

CAS number

71125-38-7

InChI Key

ZRVUJXDFFKFLMG-UHFFFAOYSA-N

InChI

InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19)

IUPAC Name

4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1lambda6,2-benzothiazine-3-carboxamide

SMILES

CN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=O

References

Synthesis Reference

Laura Coppi, "Crystalline forms of meloxicam and processes for their preparation and interconversion." U.S. Patent US20030109701, issued June 12, 2003.

US20030109701

General References

1. Bekker A, Kloepping C, Collingwood S: Meloxicam in the management of post-operative pain: Narrative review. J Anaesthesiol Clin Pharmacol. 2018 Oct-Dec;34(4):450-457. doi: 10.4103/joacp.JOACP_133_18. [Article]
2. Moore RA, Derry S, McQuay HJ: Single dose oral meloxicam for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007552. doi: 10.1002/14651858.CD007552.pub2. [Article]
3. Turck D, Roth W, Busch U: A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol. 1996 Apr;35 Suppl 1:13-6. doi: 10.1093/rheumatology/35.suppl_1.13. [Article]
4. Katz JA: COX-2 inhibition: what we learned--a controversial update on safety data. Pain Med. 2013 Dec;14 Suppl 1:S29-34. doi: 10.1111/pme.12252. [Article]
5. Seddik H, Rabhi M: [Meloxicam-induced colitis revealed by acute abdominal pain]. Ann Pharm Fr. 2013 Mar;71(2):119-22. doi: 10.1016/j.pharma.2012.12.003. Epub 2013 Mar 8. [Article]
6. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T: Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica. 1998 Jan;28(1):1-13. doi: 10.1080/004982598239704. [Article]
7. Ricciotti E, FitzGerald GA: Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011 May;31(5):986-1000. doi: 10.1161/ATVBAHA.110.207449. [Article]
8. Prasad GS, Srisailam K, Sashidhar RB: Metabolic inhibition of meloxicam by specific CYP2C9 inhibitors in Cunninghamella blakesleeana NCIM 687: in silico and in vitro studies. Springerplus. 2016 Feb 24;5:166. doi: 10.1186/s40064-016-1794-4. eCollection 2016. [Article]
9. Carl P. Weiner MD, MBA, FACOG, Clifford Mason PhD (2019). Drugs for Pregnant and Lactating Women (3rd ed.). Elsevier.
10. FDA approved products: Mobic (meloxicam) oral tablets [Link]
11. Medsafe NZ: Mobictab (meloxicam) oral tablets [Link]
12. American College of Cardiology: Meloxicam [Link]
13. FDA Approved Drug Products: ZYNRELEF (bupivacaine and meloxicam) extended-release solution for injection [Link]

External Links

Human Metabolome Database

HMDB0014952

KEGG Drug

D00969

KEGG Compound

C08169

PubChem Compound

54677470

PubChem Substance

46506624

ChemSpider

10442740

BindingDB

50056998

RxNav

41493

ChEBI

6741

ChEMBL

CHEMBL599

ZINC

ZINC000013129998

Therapeutic Targets Database

DAP000971

PharmGKB

PA450353

PDBe Ligand

MXM

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Meloxicam

PDB Entries

4m11 / 4o1z

FDA label

Download (45.4 KB)

MSDS

Download (35.7 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">

Phase	Status	Purpose	Conditions	Count
4	Completed	Treatment	Biliary Atresia, Kasai Portoenterostomy Status	1
4	Completed	Treatment	Healthy Subjects (HS)	1
4	Completed	Treatment	Osteoarthritis (OA)	3
4	Completed	Treatment	Osteoarthritis (OA) / Rheumatoid Arthritis	1
4	Completed	Treatment	Pharyngitis	1

Pharmacoeconomics

Manufacturers

• Boehringer ingelheim pharmaceuticals inc
• Actavis totowa llc
• Apotex inc etobicoke site
• Aurobindo pharma ltd
• Beijing double crane pharmaceutical co ltd
• Beijing yabao biopharmaceutical co ltd
• Breckenridge pharmaceutical inc
• Caraco pharmaceutical laboratories ltd
• Carlsbad technology inc
• Corepharma llc
• Dr reddys laboratories inc
• Genpharm inc
• Glenmark generics ltd
• Lupin pharmaceuticals inc
• Mutual pharmaceutical co inc
• Mylan pharmaceuticals inc
• Roxane laboratories inc
• Strides arcolab ltd
• Taro pharmaceutical industries ltd
• Teva pharmaceuticals usa
• Unichem laboratories ltd
• Watson laboratories inc
• Zydus pharmaceuticals usa inc

Packagers

• 4uOrtho LLC
• Advanced Pharmaceutical Services Inc.
• Aidarex Pharmacuticals LLC
• Apotex Inc.
• Apotheca Inc.
• A-S Medication Solutions LLC
• Aurobindo Pharma Ltd.
• Blenheim Pharmacal
• Boehringer Ingelheim Ltd.
• Breckenridge Pharmaceuticals
• Bryant Ranch Prepack
• Cadila Healthcare Ltd.
• Cadista Pharmaceuticals Inc.
• Caraco Pharmaceutical Labs
• Carlsbad Technology Inc.
• Cipla Ltd.
• Corepharma LLC
• Dispensing Solutions
• Diversified Healthcare Services Inc.
• Doctor Reddys Laboratories Ltd.
• Dorx LLC
• Genpharm LP
• Glenmark Generics Ltd.
• H.J. Harkins Co. Inc.
• Innoviant Pharmacy Inc.
• International Laboratories Inc.
• Keltman Pharmaceuticals Inc.
• Lake Erie Medical and Surgical Supply
• Lannett Co. Inc.
• Lupin Pharmaceuticals Inc.
• Mallinckrodt Inc.
• Medisca Inc.
• Murfreesboro Pharmaceutical Nursing Supply
• Mylan
• Nucare Pharmaceuticals Inc.
• Palmetto Pharmaceuticals Inc.
• PD-Rx Pharmaceuticals Inc.
• Physicians Total Care Inc.
• Preferred Pharmaceuticals Inc.
• Prepak Systems Inc.
• Rebel Distributors Corp.
• Remedy Repack
• Resource Optimization and Innovation LLC
• Roxane Labs
• Sandoz
• Southwood Pharmaceuticals
• St Mary's Medical Park Pharmacy
• Stat Rx Usa
• Strides Arcolab Limited
• Taro Pharmaceuticals USA
• Teva Pharmaceutical Industries Ltd.
• UDL Laboratories
• Unichem Laboratories Ltd.
• Vangard Labs Inc.
• Yung Shin Pharmaceutical Industry Ltd.
• Zydus Pharmaceuticals

Dosage Forms

Form	Route	Strength
Injection	Intravenous	30 mg/1mL
Tablet	Oral	7.50 mg
Tablet	Oral	15.000 mg
Tablet	Oral	15.0 mg
Capsule, liquid filled	Oral	7.5 mg
Capsule, liquid filled	Oral	15 mg
Suppository	Rectal
Kit	Oral	15 mg/1
Solution	Ophthalmic	0.300 mg
Capsule	Oral	15.000 mg
Capsule	Oral
Tablet	Oral
Capsule	Oral	7.500 mg
Solution	Parenteral	15.000 mg
Gel	Cutaneous
Injection	Intramuscular	15 mg/1.5ml
Tablet, film coated	Oral
Solution		15.000 mg
Tablet	Oral	15.00 mg
Capsule, coated	Oral	7.5 mg
Capsule, coated	Oral	15 mg
Solution	Parenteral	15 mg
Injection, solution	Intramuscular	15 mg/1.5ml
Solution	Intramuscular	15 mg
Tablet, orally disintegrating	Oral	1500000 mg
Capsule	Oral
Injection, solution	Intramuscular
Injection, solution
Tablet	Oral	15 mg
Tablet	Oral	1500000 mg
Solution	Intramuscular	1500000 mg
Tablet, soluble	Oral	15 mg
Tablet, soluble	Oral	7.5 mg
Tablet	Oral	7.5 mg
Suspension	Oral	7.5 mg/5mL
Tablet	Oral	15 mg/1
Tablet	Oral	7.5 mg/1
Tablet, orally disintegrating	Oral	15 mg
Tablet	Oral
Injection, solution	Parenteral
Tablet, coated	Oral	15 mg
Tablet, coated	Oral	7.5 mg
Injection	Intramuscular	15 mg
Capsule	Oral	15 MG
Capsule	Oral	7.5 mg
Suppository	Rectal	7.5 mg
Injection
Injection	Parenteral	15 mg
Capsule, coated	Oral	750000 mg
Capsule, coated	Oral	1500000 mg
Kit	Oral; Topical
Solution	Parenteral	15.000 mg
Tablet	Oral	100.000 mg
Tablet, coated	Oral
Gel	Topical	1 g
Tablet, delayed release	Oral
Solution	Conjunctival; Ophthalmic	0.3 mg
Solution	Ophthalmic	0.3 mg
Suppository	Rectal	15 MG
Capsule	Oral	15.000 mg
Solution	Intramuscular	15.000 mg
Tablet	Oral	7.500 mg
Tablet, orally disintegrating	Oral	15 mg/1
Tablet, orally disintegrating	Oral	7.5 mg/1
Tablet	Oral	750000 mg
Capsule, coated	Oral
Kit	Oral
Injection, solution		15 mg/1.5ml
Capsule	Oral	10 mg/1
Capsule	Oral	5 mg/1
Solution	Infiltration
Solution	Intralesional
Solution, gel forming, extended release	Infiltration

Prices

Unit description	Cost	Unit
Meloxicam 7.5 mg/5ml Suspension 100ml Bottle	86.99USD	bottle
Meloxicam bp powder	56.61USD	g
Mobic 15 mg tablet	7.37USD	tablet
Meloxicam 15 mg tablet	4.94USD	tablet
Mobic 7.5 mg tablet	4.74USD	tablet
Meloxicam 7.5 mg tablet	3.23USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
US6184220	Yes	2001-02-06	2019-09-25
US9649318	No	2017-05-16	2035-03-31
US9526734	No	2016-12-27	2033-03-31
US9808468	No	2017-11-07	2035-03-31
US8545879	No	2013-10-01	2030-08-31
US9974746	No	2018-05-22	2030-05-26
US8512727	No	2013-08-20	2022-12-25
US10471067	No	2019-11-12	2024-02-24
US10463673	No	2019-11-05	2024-02-24
US10709713	No	2020-07-14	2030-05-26
US10881663	No	2021-01-05	2039-03-08
US9592227	No	2017-03-14	2034-03-13
US9694079	No	2017-07-04	2035-04-20
US9801945	No	2017-10-31	2035-04-20
US10213510	No	2019-02-26	2035-04-20
US9913909	No	2018-03-13	2034-03-13
US10098957	No	2018-10-16	2035-04-20
US10632199	No	2020-04-28	2035-04-20
US10898575	No	2021-01-26	2035-04-20
US10980886	No	2021-04-20	2035-04-20
US10398686	No	2019-09-03	2034-03-13
US9744163	No	2017-08-29	2034-03-13
US11083797	No	2021-08-10	2035-04-20
US11083730	No	2021-08-10	2035-04-20
US11253504	No	2014-03-13	2034-03-13
US11253478	No	2010-05-26	2030-05-26
US11413350	No	2015-04-20	2035-04-20
US11458145	No	2019-03-08	2039-03-08
US11844837	No	2016-04-21	2036-04-21

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	256	http://www.guildlink.com.au/gc/ws/by/pi.cfm?product=bypmobic10517
boiling point (°C)	581.3±60.0	https://www.chemsrc.com/en/cas/71125-38-7_1083007.html
water solubility	22 mg/ml	https://www.chemicalbook.com/ChemicalProductProperty_US_CB2191355.aspx
logP	0.1	https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20938s004lbl.pdf
Caco2 permeability	-4.71	ADME Research, USCD
pKa	4.08	https://www.chemicalbook.com/ChemicalProductProperty_US_CB2191355.aspx

Predicted Properties

Property	Value	Source
Water Solubility	0.154 mg/mL	ALOGPS
logP	2.28	ALOGPS
logP	1.6	Chemaxon
logS	-3.4	ALOGPS
pKa (Strongest Acidic)	4.47	Chemaxon
pKa (Strongest Basic)	0.47	Chemaxon
Physiological Charge	-1	Chemaxon
Hydrogen Acceptor Count	5	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	99.6 Å2	Chemaxon
Rotatable Bond Count	2	Chemaxon
Refractivity	88.62 m3·mol-1	Chemaxon
Polarizability	34.25 Å3	Chemaxon
Number of Rings	3	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9156
Blood Brain Barrier	-	0.9811
Caco-2 permeable	+	0.8484
P-glycoprotein substrate	Substrate	0.5181
P-glycoprotein inhibitor I	Non-inhibitor	0.7516
P-glycoprotein inhibitor II	Non-inhibitor	0.7491
Renal organic cation transporter	Non-inhibitor	0.9275
CYP450 2C9 substrate	Substrate	0.5637
CYP450 2D6 substrate	Non-substrate	0.9117
CYP450 3A4 substrate	Non-substrate	0.6649
CYP450 1A2 substrate	Non-inhibitor	0.9271
CYP450 2C9 inhibitor	Inhibitor	0.5511
CYP450 2D6 inhibitor	Non-inhibitor	0.9322
CYP450 2C19 inhibitor	Non-inhibitor	0.8948
CYP450 3A4 inhibitor	Non-inhibitor	0.8191
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.7316
Ames test	Non AMES toxic	0.8576
Carcinogenicity	Non-carcinogens	0.7052
Biodegradation	Not ready biodegradable	0.9312
Rat acute toxicity	3.4619 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9579
hERG inhibition (predictor II)	Non-inhibitor	0.7999

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	splash10-014i-2902000000-442e82736bdaa71629b1
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	splash10-0uxr-0905000000-155a653652a8dc132b5c
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	splash10-001i-1390000000-e476bc93f0f2236bccdc
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	splash10-0006-3910000000-5a451a906b9cf9bd15b8
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0udi-0009000000-d860614369de32fc5b55
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-00kf-0901000000-0d362af6b48e1604f3c0
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0006-0900000000-f79d2bd45c77067c33bf
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0006-0900000000-385da9c2b565923f3591
LC-MS/MS Spectrum - LC-ESI-QTOF , positive	LC-MS/MS	splash10-0006-0900000000-24d8592c133da8552647
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0uxr-0905000000-155a653652a8dc132b5c
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0uxu-2905000000-a1d5ee29626527977b8e
MS/MS Spectrum - , positive	LC-MS/MS	splash10-014l-3900000000-835e2ce927e75b3bb1fb
MS/MS Spectrum - , positive	LC-MS/MS	splash10-014l-3910000000-cf38e48efa983293e01f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0udi-0409000000-9eed4b12704671db2e97
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-000i-0090000000-92a7e97b9e94354676cb
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-03di-5902000000-90366665d4fb43a2582e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-000i-2590000000-fb774373bdf669e01f62
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-03xs-1920000000-e9e6c6baf2ce62ed1c61
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-03di-4920000000-d5f1d2f628c48ca8e924
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	179.1804435	predicted	DarkChem Lite v0.1.0
[M-H]-	176.2488148	predicted	DarkChem Lite v0.1.0
[M-H]-	179.0166435	predicted	DarkChem Lite v0.1.0
[M-H]-	172.37029	predicted	DeepCCS 1.0 (2019)
[M+H]+	179.7855435	predicted	DarkChem Lite v0.1.0
[M+H]+	182.3316962	predicted	DarkChem Lite v0.1.0
[M+H]+	179.5988435	predicted	DarkChem Lite v0.1.0
[M+H]+	174.72829	predicted	DeepCCS 1.0 (2019)
[M+Na]+	179.3430435	predicted	DarkChem Lite v0.1.0
[M+Na]+	177.8970435	predicted	DarkChem Lite v0.1.0
[M+Na]+	178.8203435	predicted	DarkChem Lite v0.1.0
[M+Na]+	181.1515	predicted	DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	490	N/A	N/A	A28995
IC 50 (nM)	160	N/A	N/A	A28996
IC 50 (nM)	700	N/A	N/A	A27760
Ki (nM)	2100	N/A	N/A	A27471
Ki (nM)	230	N/A	N/A	A27471
Ki (nM)	700	N/A	N/A	A27783 / A27790

Details

Binding Properties1. Prostaglandin G/H synthase 2

Kind

Protein

Organism

Humans

Pharmacological action

Yes

Actions

Inhibitor

General Function

Prostaglandin-endoperoxide synthase activity

Specific Function

Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...

Gene Name

PTGS2

Uniprot ID

P35354

Uniprot Name

Prostaglandin G/H synthase 2

Molecular Weight

68995.625 Da

References

1. Poulsen Nautrup B, Horstermann D: [Pharmacodynamic and pharmacokinetic aspects of the non-inflammatory non-steroidal agent meloxicam in dogs]. Dtsch Tierarztl Wochenschr. 1999 Mar;106(3):94-100. [Article]
2. Tegeder I, Lotsch J, Krebs S, Muth-Selbach U, Brune K, Geisslinger G: Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin Pharmacol Ther. 1999 May;65(5):533-44. [Article]
3. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [Article]
4. Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P: Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999 Jul;290(1):276-80. [Article]
5. Gross JM, Dwyer JE, Knox FG: Natriuretic response to increased pressure is preserved with COX-2 inhibitors. Hypertension. 1999 Nov;34(5):1163-7. [Article]
6. Bekker A, Kloepping C, Collingwood S: Meloxicam in the management of post-operative pain: Narrative review. J Anaesthesiol Clin Pharmacol. 2018 Oct-Dec;34(4):450-457. doi: 10.4103/joacp.JOACP_133_18. [Article]
7. Gates BJ, Nguyen TT, Setter SM, Davies NM: Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Expert Opin Pharmacother. 2005 Oct;6(12):2117-40. doi: 10.1517/14656566.6.12.2117. [Article]
8. FDA approved products: Mobic (meloxicam) oral tablets [Link]

Binding Properties

×

Property	Measurement	pH	Temperature (°C)	References
IC 50 (nM)	1400	N/A	N/A	A27760

Details

Binding Properties2. Prostaglandin G/H synthase 1

Kind

Protein

Organism

Humans

Pharmacological action

Unknown

Actions

Inhibitor

General Function

Prostaglandin-endoperoxide synthase activity

Specific Function

Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...

Gene Name

PTGS1

Uniprot ID

P23219

Uniprot Name

Prostaglandin G/H synthase 1

Molecular Weight

68685.82 Da

References

1. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [Article]
2. Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P: Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999 Jul;290(1):276-80. [Article]
3. Bekker A, Kloepping C, Collingwood S: Meloxicam in the management of post-operative pain: Narrative review. J Anaesthesiol Clin Pharmacol. 2018 Oct-Dec;34(4):450-457. doi: 10.4103/joacp.JOACP_133_18. [Article]
4. Gates BJ, Nguyen TT, Setter SM, Davies NM: Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Expert Opin Pharmacother. 2005 Oct;6(12):2117-40. doi: 10.1517/14656566.6.12.2117. [Article]
5. FDA approved products: Mobic (meloxicam) oral tablets [Link]

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55